Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Single-Arm, Open Label, Interventional Phase II Clinical Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy

Trial Profile

Single-Arm, Open Label, Interventional Phase II Clinical Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy

Recruiting
Phase of Trial: Phase II

Latest Information Update: 30 Jan 2019

At a glance

  • Drugs Busulfan (Primary) ; Cyclophosphamide (Primary) ; Fludarabine (Primary) ; Granulocyte colony-stimulating factors (Primary) ; Melphalan (Primary) ; Mycophenolate mofetil (Primary) ; Mycophenolate mofetil (Primary) ; Spanlecortemlocel (Primary) ; Tacrolimus (Primary)
  • Indications Haematological malignancies
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Jan 2019 Planned primary completion date changed from 1 Jun 2023 to 1 Jul 2023.
    • 02 Jan 2019 Planned End Date changed from 1 Jun 2023 to 1 Aug 2023.
    • 02 Jan 2019 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top